Abbott receives CE mark for world's first dual chamber leadless pacemaker system

American firm Abbott has received CE Mark in Europe for the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms.

Approximately 49 million people are living with cardiovascular disease in the European Union, and it is estimated that 14.4 million people 65 and older will have atrial fibrillation by 2060. AVEIR DR is a breakthrough innovation that enables the world's first beat-to-beat, wireless communication between two leadless pacemakers, designed to address the needs of people living with abnormal heart rhythms and expand treatment options in Europe.

The AVEIR DR leadless pacemaker system utilises a new method of delivering dual chamber therapy as it is comprised of two unique devices – one that paces the right ventricle (AVEIR VR) and one that paces the right atrium (AVEIR AR). Each device is roughly one-tenth the size of a traditional pacemaker and smaller than a AAA battery.

Through Abbott's proprietary i2i™ (implant-to-implant) communication technology, AVEIR DR provides synchronised pacing between two leadless pacemakers on every heartbeat based on a person's clinical needs.